Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AZUL +7.7%, SSL +5.4%, VLRS +4.1%, KOS +3.5%, SMMT +2.8%, OC +2.1%, BRK.B +1%
Other news:
- IOBT +15.5% (Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference)
- TRDA +7.4% (FDA has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102)
- AB +5% (Equitable Holding (EQH) commenced a cash tender offer to purchase up to 46,000,000 units representing assignments of beneficial ownership of limited partnership interests in AllianceBernstein at a price of $38.50 per Unit)
- NOTE +5% (announces definitive agreement to divest additional non-core assets to fuel policy-focused growth, boost profitability, and strengthen balance sheet) SOPH +4.2% (leading healthcare institutions adopt MSK-ACCESS for Liquid Biopsy Testing)
- MTAL +2.4% (announces 2024 resource and reserve statement and production guidance)
- TLX +2.1% (receives approval for Illuccix PSMA-PET Imaging Agent in Norway)
- CLLS +2% (Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025)
- TXG +1.8% (Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis)
- EQH +1.8% (RGA Announces Reinsurance Transaction with Equitable Holdings)
- NGG +1.5% (announces that it has agreed to sell its National Grid Renewables US onshore renewables business to Brookfield Asset Management)
- MAG +1.3% (provides exploration update and outlook for larder and deer trail projects)
- AXSM +0.9% (Announces SYMBRAVO (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors)
- GSK +0.8% (commences stock buyback program)
Analyst comments:
- TWLO +3.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- NKE +2.3% (upgraded to Buy from Hold at Jefferies)
- WING +1.7% (upgraded to Buy from Neutral at Guggenheim)
- CARR +1.6% (upgraded to Outperform from Peer Perform at Wolfe Research)
- RTX +1% (upgraded to Buy from Neutral at UBS)